193 related articles for article (PubMed ID: 35192607)
1. LRRK2 dynamics analysis identifies allosteric control of the crosstalk between its catalytic domains.
Weng JH; Aoto PC; Lorenz R; Wu J; Schmidt SH; Manschwetus JT; Kaila-Sharma P; Silletti S; Mathea S; Chatterjee D; Knapp S; Herberg FW; Taylor SS
PLoS Biol; 2022 Feb; 20(2):e3001427. PubMed ID: 35192607
[TBL] [Abstract][Full Text] [Related]
2. Conformation and dynamics of the kinase domain drive subcellular location and activation of LRRK2.
Schmidt SH; Weng JH; Aoto PC; Boassa D; Mathea S; Silletti S; Hu J; Wallbott M; Komives EA; Knapp S; Herberg FW; Taylor SS
Proc Natl Acad Sci U S A; 2021 Jun; 118(23):. PubMed ID: 34088839
[TBL] [Abstract][Full Text] [Related]
3. Capturing the domain crosstalk in full length LRRK2 and LRRK2RCKW.
Störmer E; Weng JH; Wu J; Bertinetti D; Kaila Sharma P; Ma W; Herberg FW; Taylor S
Biochem J; 2023 May; 480(11):815-33. PubMed ID: 37212165
[TBL] [Abstract][Full Text] [Related]
4. Role of the leucine-rich repeat protein kinase 2 C-terminal tail in domain cross-talk.
Sharma PK; Weng JH; Manschwetus JT; Wu J; Ma W; Herberg FW; Taylor SS
Biochem J; 2024 Feb; 481(4):313-327. PubMed ID: 38305364
[TBL] [Abstract][Full Text] [Related]
5. The Roc-COR tandem domain of leucine-rich repeat kinase 2 forms dimers and exhibits conventional Ras-like GTPase properties.
Mills RD; Liang LY; Lio DS; Mok YF; Mulhern TD; Cao G; Griffin M; Kenche VB; Culvenor JG; Cheng HC
J Neurochem; 2018 Nov; 147(3):409-428. PubMed ID: 30091236
[TBL] [Abstract][Full Text] [Related]
6. Capturing Differences in the Regulation of LRRK2 Dynamics and Conformational States by Small Molecule Kinase Inhibitors.
Weng JH; Ma W; Wu J; Sharma PK; Silletti S; McCammon JA; Taylor S
ACS Chem Biol; 2023 Apr; 18(4):810-821. PubMed ID: 37043829
[TBL] [Abstract][Full Text] [Related]
7. The dynamic switch mechanism that leads to activation of LRRK2 is embedded in the DFGψ motif in the kinase domain.
Schmidt SH; Knape MJ; Boassa D; Mumdey N; Kornev AP; Ellisman MH; Taylor SS; Herberg FW
Proc Natl Acad Sci U S A; 2019 Jul; 116(30):14979-14988. PubMed ID: 31292254
[TBL] [Abstract][Full Text] [Related]
8. Doubly Constrained C-terminal of Roc (COR) Domain-Derived Peptides Inhibit Leucine-Rich Repeat Kinase 2 (LRRK2) Dimerization.
Pathak P; Alexander KK; Helton LG; Kentros M; LeClair TJ; Zhang X; Ho FY; Moore TT; Hall S; Guaitoli G; Gloeckner CJ; Kortholt A; Rideout H; Kennedy EJ
ACS Chem Neurosci; 2023 Jun; 14(11):1971-1980. PubMed ID: 37200505
[TBL] [Abstract][Full Text] [Related]
9. Structure and nucleotide-induced conformational dynamics of the
Deyaert E; Leemans M; Singh RK; Gallardo R; Steyaert J; Kortholt A; Lauer J; Versées W
Biochem J; 2019 Jan; 476(1):51-66. PubMed ID: 30538153
[TBL] [Abstract][Full Text] [Related]
10. Kinase Domain Is a Dynamic Hub for Driving LRRK2 Allostery.
Taylor SS; Kaila-Sharma P; Weng JH; Aoto P; Schmidt SH; Knapp S; Mathea S; Herberg FW
Front Mol Neurosci; 2020; 13():538219. PubMed ID: 33122997
[TBL] [Abstract][Full Text] [Related]
11. Crystal structure of the WD40 domain dimer of LRRK2.
Zhang P; Fan Y; Ru H; Wang L; Magupalli VG; Taylor SS; Alessi DR; Wu H
Proc Natl Acad Sci U S A; 2019 Jan; 116(5):1579-1584. PubMed ID: 30635421
[TBL] [Abstract][Full Text] [Related]
12. Insights into the Influence of Specific Splicing Events on the Structural Organization of
Vlachakis D; Labrou NE; Iliopoulos C; Hardy J; Lewis PA; Rideout H; Trabzuni D
Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30223621
[TBL] [Abstract][Full Text] [Related]
13. Understanding the GTPase Activity of LRRK2: Regulation, Function, and Neurotoxicity.
Nguyen AP; Moore DJ
Adv Neurobiol; 2017; 14():71-88. PubMed ID: 28353279
[TBL] [Abstract][Full Text] [Related]
14. The Parkinson's disease-associated mutation N1437H impairs conformational dynamics in the G domain of LRRK2.
Huang X; Wu C; Park Y; Long X; Hoang QQ; Liao J
FASEB J; 2019 Apr; 33(4):4814-4823. PubMed ID: 30592623
[TBL] [Abstract][Full Text] [Related]
15. Molecular Modeling Study on the Interaction Mechanism between the LRRK2 G2019S Mutant and Type I Inhibitors by Integrating Molecular Dynamics Simulation, Binding Free Energy Calculations, and Pharmacophore Modeling.
Tan S; Zhang Q; Wang J; Gao P; Xie G; Liu H; Yao X
ACS Chem Neurosci; 2022 Mar; 13(5):599-612. PubMed ID: 35188741
[TBL] [Abstract][Full Text] [Related]
16. Allosteric inhibition of LRRK2, where are we now.
Soliman A; Cankara FN; Kortholt A
Biochem Soc Trans; 2020 Oct; 48(5):2185-2194. PubMed ID: 33079169
[TBL] [Abstract][Full Text] [Related]
17. Markov State Models and Molecular Dynamics Simulations Provide Understanding of the Nucleotide-Dependent Dimerization-Based Activation of LRRK2 ROC Domain.
Li X; Qi Z; Ni D; Lu S; Chen L; Chen X
Molecules; 2021 Sep; 26(18):. PubMed ID: 34577121
[TBL] [Abstract][Full Text] [Related]
18. How Parkinson's disease-related mutations disrupt the dimerization of WD40 domain in LRRK2: a comparative molecular dynamics simulation study.
Li X; Ye M; Wang Y; Qiu M; Fu T; Zhang J; Zhou B; Lu S
Phys Chem Chem Phys; 2020 Sep; 22(36):20421-20433. PubMed ID: 32914822
[TBL] [Abstract][Full Text] [Related]
19. Molecular insights of the G2019S substitution in LRRK2 kinase domain associated with Parkinson's disease: A molecular dynamics simulation approach.
Agrahari AK; Doss GPC; Siva R; Magesh R; Zayed H
J Theor Biol; 2019 May; 469():163-171. PubMed ID: 30844370
[TBL] [Abstract][Full Text] [Related]
20. The LRRK2 N-terminal domain influences vesicle trafficking: impact of the E193K variant.
Marku A; Carrion MDP; Pischedda F; Marte A; Casiraghi Z; Marciani P; von Zweydorf F; Gloeckner CJ; Onofri F; Perego C; Piccoli G
Sci Rep; 2020 Mar; 10(1):3799. PubMed ID: 32123243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
